Therefore, since the response to therapy require the EGFR target to be present, the development of BOI methods for quantitative detection of EGFR protein levels in CRC primary and secondary tumor tissues is necessary, in order to guide the treatment of individual selected for EGFR targeted antibody treatment and in particular those who relapse while on EGFR targeting therapies [13]. This evidence concerns the gene EGFR and neoplasm.